PARPi after PARPi in epithelial ovarian cancer

The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review of ovarian cancer patients who received ≥2 li...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Gynecol Oncol Rep
Glavni autori: Essel, K.G., Behbakht, K., Lai, T., Hand, L., Evans, E., Dvorak, J., Ding, K., Konecny, G., Moore, K.N.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2021
Teme:
Case Series
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7840844/
https://ncbi.nlm.nih.gov/pubmed/33537389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100699
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items